Rideout Health Cancer Center Annual Report 2016

Rideout Health Cancer Center Annual Report 2016 The Rideout Cancer Center (RCC) in partnership with UC Davis Health provides cancer patients with the most up-todate and effective cancer care in the Yuba-Sutter community. UC Davis is a National Cancer Institute (NCI) designated cancer center, one of 44 nationwide, which comprises research, clinical trials and the latest technology in cancer care. Our partnership with UC Davis sets high standards in providing quality care to patients. Patients receive quality care they might expect from a large university medical center with the compassion and personalization of a community based hospital. The Rideout Cancer Center is accredited by the American College of Surgeons Commission on Cancer (ACoS CoC) as a Comprehensive Community Cancer Program. This accreditation requires us to follow high standards of care and provide a more comprehensive approach to cancer treatment. Our 42,000 square foot cancer center integrates care management, Radiation Oncology, PET/CT Services, Medical Oncology (Chemotherapy), Hematology (Blood Diseases) and Clinical Trials with a team of highly trained board certified Physicians, Oncology Certified Nurses (OCN s) and certified Radiation Therapists. All of these services are offered under one roof because we have found that a comprehensive, integrated treatment strategy more effectively treats the whole person physically and emotionally. Our team is dedicated to helping you and your families develop the right treatment plan and access to all the services you need to cope with cancer. We have worked hard to provide the latest options for cancer treatment with the highest quality of care. We are grateful for the dedicated support from our survivors, family and friends and look forward to what the future brings. The Cancer Center has made a significant difference in so many lives and we hope it continues for years to come. Scott Christensen, MD, Director Rideout Health Cancer Center INSIDE THIS ISSUE Prevention Program... 2 Community Outreach... 3 Program Goals... 4 Clinical Trials... 4 Activities Report... 5 Cancer Data..6 2016 data....7 Mission Statement.8 1

2016 CANCER CENTER NEWS Prevention Program 2016 Every year Rideout health initiates a prevention program aimed at reducing the incidence of cancer. 2016 Prevention Program: To reduce the incidence of skin cancer within the community through education, cancer risk awareness and teaching the ABCDE s of Melanoma identification for self-detection. Topic: Melanoma is a deadly form of skin cancer. The American Cancer Society (ACS) estimates that about 83,510 new melanomas will be diagnosed in the US during 2016, resulting in about 13,650 deaths. This makes up 5% of the total cancers expected. California is expected to have approximately 8,560 new melanoma cases, 5% according to the ACS. In the ACS California Fact and Figures 2014, Yuba and Sutter counties were expected to have 7% of the cancer population with a diagnosis of melanoma. Early detection of melanoma can significantly reduce extensive treatment and mortality. Patients play an important role in detection of their own melanomas. Target population- Cancer patient through the resource desk at RH Cancer Center, Cancer Center Patient packets and FRGH employees via email education. Rationale: To provide a prevention program for an at risk population through education of skin cancer From Cancer Patient to Cancer Survivor: Survivorship Care THE INSTITUTE OF HEALTH recommends that patients with cancer who are completing their first course of treatment be provided with a comprehensive care summary and follow-up plan that is clearly and effectively explained. The CoC recognizes the importance for cancer programs to develop a process to ensure a survivorship care plan is provided to patients as a standard of care. RIDEOUT HEALTH 2016 GOAL Cancer survivors who are treated with curative intent and have completed active therapy (other than long-term hormonal therapy) from all disease sites will have a survivorship care plan which was implemented Spring 2015, using Journey Forward, a Cancer Survivorship Care Plan Builder. Head and Neck cancer patients and Radiation patients were the first group to receive survivorship plans. Prostate and DCIS and other Breast cancer patients were added to the group. 2 2 200 patients (radiation & medical oncology) met the 2015 criteria and 22 (25%) survivorship care plans completed and given to patients.

OUTREACH 2016 Every year Rideout Health reaches out to the community in different ways, sponsoring health fairs, screening/ prevention events and education activities. Date Topic Facilitator (s) # Attendees Group 3/05/16 Colon Cancer-New Earth Market Health Fair INFORMATION/PREVENTION 3/31/16 Cancer L. Yatman Cancelled due to weather L. Yatman/S. Thomas Community 24 Indian Tribal Health Community-Colusa INFORMATION/PREVENTION 4/28/16 Colon Cancer/Lifestyle Changes to Prevent Cancer INFORMATION/PREVENTION 5/12/16 Nursing-Career Fair INFORMATION 5/26/16 Cancer Survivorship Rideout Cancer Center Finish Strong 6/18/16 Cancer-Valley Muffler Car Show 3 Melanoma and Skin Cancer INFORMATION/PREVENTION 9/14/16 Low-Cost Prostate Cancer Screening (Prostate Support Group assisting) SCREENING 9/20/16 Senior Resource Fair INFORMATION 10/05/16 Women s Full Health Exam CBE, Pap Smear SCREENING 10/17/16 Tobacco Use Prevention Education Tobacco Prevention Toolkit (developed by Stanford University) INFORMATION 10/2016 Low Cost Mammograms SCREENING L. Yatman/S. Thomas/American Cancer Society 150 Colusa Casino Employees S. Thomas 60 Albert Powell Students Staff 75 Cancer Survivors and Caregivers L. Yatman/J. Morgan 250 attended Community 100 + took test Sutter Health 23 PSA, 4 elevated Community L. Yatman 50 Community Sutter Medical Foundation- Brownsville and Yuba City (2) offices J. Morgan/L. Yatman Sutter Medical Foundation, Sutter Buttes Imaging, Yuba City Advanced Imaging 101 Pap Smear, 2 abnormal 2 students 16 or 18 educators Underserved and Uninsured women Marysville High School Student Mentors Underserved and Unnsured women 3

CANCER PROGRAM GOALS Programmatic Goal HPV Vaccination Awareness Specific- Provide HPV education for healthcare professionals to promote HPV vaccination as a way to decrease incidence of HPV related cancers by September 2016. In 2015, six of eight head and neck patients treated at the Rideout Cancer Center were HPV positive. Human Papillomavirus (HPV) is associated with cervical, vulvar, and vaginal cancers in females, penile cancer in males, and anal cancer and /or oropharyngeal cancer in both females and males (Petrosky, 2015). While HPV vaccination is recommended for routine vaccination at age 11 or 12, data suggests that just over half of 13-17 year old females and around 40% of males in the US have received one or more doses of HPV vaccine, and only around 35% of females and 20% of males have completed the 3-dose regimen (CDC, 2016). Health care provider recommendation has shown to be a strong predictor of vaccination. Therefore, one potential reason for the low levels of HPV vaccination rates is that adolescents and parents are not receiving HPV vaccination recommendations from their health care provider (Ylitalo 2013). Utilizing the CDC: You are the key to HPV cancer prevention, a pilot training will be provided to a pediatric provider partner who will also provide vaccination rates pre and post-intervention. Clinical Goal Nutritional Support to Head and Neck Patients Specific-Nutritional support has rarely available to our head and neck patients with the exception of those referred out of our facility. Ten patients were admitted in 2016 for nutritional failure to thrive. The implementation of nutritional support in the head and neck patient navigation program will improve quality of life for patients undergoing chemotherapy/ radiation and yield improved outcomes. and eliminate admissions. CANCER PROGRAM CLINICAL TRIALS 2016 Enrollment Summary: 4.0 % of RCC patients enrolled Clinical Trial enrollment begins with screening patients for eligibility. In 2016, 276 patients were screened and 48 patients were enrolled. Currently there are 10 patients on follow up and 38 patients on active treatment. What is a clinical trial? A Clinical Trial is a research project conducted with cancer patients to determine if an investigational drug, procedure or device is safe and effective. Participating in a clinical trial allows the patient to play an active role in their health care. Patient may gain access to new research treatments before they are widely available. 4 4 Rideout Health is in the UC Davis Cancer Care Network. This is a unique partnership among cancer centers in Northern and Central California hospitals, allowing cutting edge care close to home. Rideout Health patients benefit from the combination of UC Davis s academic and research expertise with the personal relationships and unique insight of our community cancer center. 16 Clinical Trials are currently open at Rideout Cancer Center with newly accredited Radiation-Oncology trials and 4 trials are pending approval.

Comprehensive Community Cancer Program Annual Activities Report 2016 Quality Improvements Provide nutritional Support to Head and Neck Patients Clinical Goal Smoking prevention education in youths Lab results available prior to chemotherapy orders HPV Vaccination Awareness Continuum of Care Patient Navigation 35 Patient Consults (200% increase from 2015) Psychosocial Distress Screening Average of 76 Screenings per month Survivorship Care Plan 26% of patients have received a SCP Clinical Services Nursing Care- 67% of Nursing Staff are OCN s CAP* Protocols ->95% met standard RQRS -Enrolled Data Accuracy-99% Follow Up Rate ->90% 5 *CAP College of American Pathologist

Cumulative Survival Rate 2016 CANCER REGISTRY DATA TOP 5 SITES AJCC STAGE BREAST(26%) LUNG/BRONCHUS-NON SM CELL(19.4%) PROSTATE(8%) HEMERETIC(7.8%) NON-HODGKIN'S LYMPHOMA(6.6%) Stage 0(4.1%) Stage I(23.4%) Stage II(21.5%) Stage III(13.1%) Stage IV(22.7%) AGE GENDER 180 160 140 120 100 80 60 40 20 0 270 260 250 240 230 220 210 200 190 MALE(45.7%) FEMALE(54.3%) TREATMENT SURVIVAL 2012-2016 1.0 Survival Report - Actuarial Method - Chart 0.9 2016 0.8 40% 30% None Surgery Radiation 0.7 0.6 0.5 Chemo 0.4 14% Hormone Combo 0.3 0.2 6 2% 8% 6% 0.1 0.0 0 1 2 3 4 5 All Stages 1.0000 0.7397 0.6466 0.6013 0.5653 0.5484 Stage I 1.0000 0.9286 0.8842 0.8380 0.8182 0.8079 Stage II 1.0000 0.8840 0.8014 0.7593 0.7039 0.6788 Stage III 1.0000 0.7942 0.6815 0.6504 0.6269 0.6110 Stage IV 1.0000 0.4625 0.3062 0.2450 0.1938 0.1770

2016 RIDEOUT HEALTH Annual Report Site Total Class Sex Stage Group Cases Analytic NonAn M F Stage 0 Stage I Stage II Stage III Stag e IV BREAST 98 91 7 0 98 12 36 27 6 9 LUNG/BRONCHUS-NON SM CELL 85 78 7 43 42 0 13 11 13 41 PROSTATE 52 36 16 52 0 0 2 19 4 10 HEMERETIC 31 26 5 22 9 0 0 0 0 1 NON-HODGKIN'S LYMPHOMA 29 27 2 17 12 0 8 6 2 11 COLON 25 24 1 10 15 0 0 7 13 3 BLADDER 22 18 4 16 6 5 3 7 1 2 UNKNOWN OR ILL-DEFINED 18 18 0 9 9 0 0 0 0 0 LIVER 16 10 6 13 3 0 2 2 2 3 LUNG/BRONCHUS-SMALL CELL 16 15 1 7 9 0 1 1 0 13 PANCREAS 14 11 3 7 7 0 1 3 1 6 THYROID 13 12 1 5 8 0 9 0 1 2 RECTUM & RECTOSIGMOID 12 12 0 9 3 0 1 3 2 5 MYELOMA 12 11 1 5 7 0 0 0 0 0 MELANOMA OF SKIN 12 7 5 10 2 0 1 4 1 1 ESOPHAGUS 11 9 2 7 4 0 2 0 2 1 TONSIL 10 8 2 8 2 0 0 1 2 4 CORPUS UTERI 10 10 0 0 10 1 5 0 2 2 TESTIS 9 7 2 9 0 0 7 0 0 0 KIDNEY AND RENAL PELVIS 8 6 2 4 4 0 3 0 1 2 TONGUE 6 5 1 5 1 0 2 0 0 1 STOMACH 5 4 1 3 2 0 2 0 0 1 OTHER NERVOUS SYSTEM 5 3 2 1 4 0 0 0 0 0 ANUS,ANAL CA- NAL,ANORECTUM 3 3 0 0 3 0 0 1 1 1 LARYNX 3 3 0 2 1 0 0 1 1 1 CERVIX UTERI 3 3 0 0 3 0 1 0 0 2 OTHER ENDOCRINE 3 3 0 1 2 0 0 0 0 0 SALIVARY GLANDS, MAJOR 2 2 0 0 2 0 0 1 1 0 MOUTH, OTHER & NOS 2 2 0 0 2 0 0 0 0 1 OROPHARYNX 2 2 0 2 0 0 0 0 1 1 OTHER DIGESTIVE 2 2 0 0 2 0 0 0 0 0 OTHER HEMATOPOIETIC 2 0 2 0 2 0 0 0 0 0 SOFT TISSUE 2 1 1 1 1 0 0 0 1 0 OVARY 2 2 0 0 2 0 0 1 0 0 BRAIN 2 1 1 1 1 0 0 0 0 0 SMALL INTESTINE 1 1 0 0 1 0 0 0 1 0 GALLBLADDER 1 1 0 0 1 0 0 0 0 1 BILE DUCTS 1 1 0 0 1 0 0 0 0 1 NASAL CAVITY,SINUS,EAR 1 1 0 0 1 0 0 0 0 1 OTHER RESPIR & THORACIC 1 1 0 0 1 0 0 0 0 0 OTHER SKIN CA 1 1 0 0 1 0 1 0 0 0 ALL SITES 0 0 0 0 0 0 0 0 0 0 7

PHYSICIANS RH CANCER PROGRAM HOA NGUYEN, MD, CAN- CER COMMITTEE CHAIR SCOTT CHRISTENSEN, DIRECTOR, CANCER CEN- TER CANCER CENTER STAFF MARGARET MURPHY, MA MELISSA SODERLUND, OCN AUBREE WARNER, RT CANCER REGISTRY STAFF GLENDA FARRELL, CTR TARALYN TAYLOR, CTR JENNIFER PERKINS, CTR MELANIE JOHNSON OUR MISSION STATEMENT To Create a healthcare environment where quality of care is a way of life and exceptional commitment is apparent to our patients, their families, our colleagues, and the community. To Fight cancer with the latest technology and educational information available to us, promoted with a caring and compassionate attitude. To Educate staff, patients, families, and the community in cancer care and treatment. Sponsor prevention and early detection programs for our community. 615 5th Street Marysville, CA 95901 To Promote growth so that changing needs of our patients and our healthcare environment are met with responsiveness, excellence and enthusiasm. (530) 749-4400 8